- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04083950
Induction de la perméabilité intestinale par un vaccin oral
This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system. Intestinal and whole-body responses will be measured in all participants before and after the vaccine.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The licensed Ty21a vaccine strain of S. enterica Typhi is routinely used by travelers to countries where typhoid is common. It is not known whether the vaccine causes measurable changes in intestinal permeability and whether changes in permeability are correlated with the magnitude of the vaccine response. In the current study, gut permeability will be measured in participants at baseline and after an aspirin challenge, which is known to disrupt intestinal permeability, and after the first, second, and fourth doses of a the Ty21a vaccine. Intestinal permeability will be measured using a three-sugar absorption test composed of lactulose, mannitol, and sucralose and by several plasma markers. Vaccine response will be measured by quantitating T cells and newly developed IgG-or IgA-secreting plasma cells specific for Ty21a.
Type d'étude
Inscription (Réel)
Phase
- Première phase 1
Contacts et emplacements
Lieux d'étude
-
-
California
-
Davis, California, États-Unis, 95616
- USDA, ARS, Western Human Nutrition Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Body Mass Index (BMI) 18.5 - 29.9 kg/m2
Exclusion Criteria:
- Has HIV/AIDS or another disease that affects the immune system
- Has any kind of cancer
- Decline to take an HIV blood test
- Blood pressure greater than or equal to 140/90 mmhg
- Pregnant or lactating women
- Refusal to take a pregnancy test prior to the study
- Refusal to use a method of birth control during the study
- Allergy to vaccine components, i.e. Thimerosal and enteric-coated capsules
- Allergy to oral typhoid vaccine
- Allergy to aspirin
- Daily use of blood thinners
- Use of anti-inflammatory medications, i.e. nonsteroidal anti-inflammatory drugs (NSAID), aspirin, 3 or more times per month
- Use of sulfonamides or antibiotics in the past 30 days
- Use of anti-hypertensive drugs, i.e. beta blockers, diuretics, calcium channel blockers
- Use of anti-malaria drugs, i.e. Mefloquine, chloroquine, and proguanil
- Use of drugs that affect the immune system, i.e. immunosuppressants, immune-modifying drugs, corticosteroids, i.e. cortisone, prednisone, methylprednisolone, for 2 weeks or longer
- Is taking cancer treatment with radiation or drugs
- Greater than ten years residence in a typhoid-endemic area
- Receipt of typhoid vaccine in the last 5 years
- Receipt of any vaccine two weeks prior to receipt of Ty21a vaccine
- Individuals at increased risk of developing complications from a live, bacterial vaccine
- History of typhoid fever
- History of primary immune deficiency or autoimmune disease
- History of acute or chronic gastrointestinal (GI) disorder, i.e. Crohn's disease, irritable bowel syndrome, gastric ulcer
- Diarrheal illness (defined as passing 3 or more abnormally loose or watery stool in a 24 hour period) or persistent vomiting 2 weeks prior to the study
- History of bleeding disorder, including bleeding from the GI tract
- History of chronic illnesses, i.e. diabetes, cardiovascular disease, cancer, gastrointestinal malabsorption or inflammatory diseases, kidney disease, autoimmune disorders, HIV, liver disease, including hepatitis B and C.
- Asthma if taking medication on a daily basis
- Recent surgery (within 3 months)
- History of GI surgery
- Recent hospitalization (within 3 months)
- Acute febrile illness (within 2 weeks)
- Unwillingness to discontinue consumption of artificial sweeteners in foods or drinks, i.e. sport drinks, coconut water, "diet" drinks and foods (possibly containing sucralose)
- Not having at least one arm vein suitable for blood drawing
- Unwilling or uncomfortable with blood draws seven times in 29 days
- Regular blood or blood product donation and refusal to suspend donation
- Current participation in another research study
- Unable to fast for 12-16 hours
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Single group
All participants will receive the vaccine and aspirin. |
One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
Autres noms:
Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in intestinal permeability
Délai: Day 1, 3, 16, 18, and 22
|
Measurement of sugar (lactulose, D-mannitol, and sucralose) excretion in urine. |
Day 1, 3, 16, 18, and 22
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Antibody response to typhoid vaccination
Délai: Day 1, 18, 22, 24, and 29
|
Measurement of Typhi-specific immunoglobulin G (IgG) and immunoglobulin A (IgA) plasma cells in peripheral blood using the antibody in lymphocyte supernatant assay. |
Day 1, 18, 22, 24, and 29
|
|
T-cell response to typhoid vaccination
Délai: Day 1, 22, and 29
|
Measurement of vaccine-specific cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T-cells in peripheral blood mononuclear cells. |
Day 1, 22, and 29
|
|
Change in markers of inflammation
Délai: Day 1, 3, 16, 18, 22, and 24
|
Measurement of plasma cytokines, chemokines, and acute phase proteins by a multiplex immunoassay. |
Day 1, 3, 16, 18, 22, and 24
|
|
Change in intestinal fatty acid binding protein (iFABP)
Délai: Day 1, 3, 16, 18, and 22
|
Measurement of plasma iFABP. |
Day 1, 3, 16, 18, and 22
|
|
Change in D-lactate
Délai: Day 1, 3, 16, 18, and 22
|
Measurement of plasma D-lactate. |
Day 1, 3, 16, 18, and 22
|
|
Change in diamine oxidase
Délai: Day 1, 3, 16, 18, and 22
|
Measurement of plasma diamine oxidase. |
Day 1, 3, 16, 18, and 22
|
|
Change in lipopolysaccharide binding protein (LBP)
Délai: Day 1, 3, 16, 18, and 22
|
Measurement of plasma LBP. |
Day 1, 3, 16, 18, and 22
|
|
Change in citrulline
Délai: Day 1, 3, 16, 18, and 22
|
Measurement of plasma citrulline. |
Day 1, 3, 16, 18, and 22
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Danielle Lemay, PhD, USDA, ARS, Western Human Nutrition Research Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Infections
- Infections bactériennes
- Infections bactériennes et mycoses
- Infections bactériennes à Gram négatif
- Infections à entérobactéries
- Infections à Salmonella
- Conditions pathologiques, signes et symptômes
- Inflammation
- La fièvre typhoïde
- Produits chimiques organiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Hydrocarbures, aromatique
- Phénols
- Dérivés de benzène
- Salicylates
- Hydroxybenzoates
- Aspirine
Autres numéros d'identification d'étude
- FL109
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .